Skip to main content

Day: September 11, 2023

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”. The Company intends to first...

Continue reading

Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

The combined company will operate as “Dianthus Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “DNTH” effective Tuesday, September 12, 2023 CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) today announced completion of the merger with Dianthus Therapeutics, Inc. (“Dianthus”) following Magenta’s successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta’s common stock immediately prior to the merger. Magenta following the merger is referred to herein as the “combined company.” Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, “We are pleased with the outcome of the special meeting and appreciate our...

Continue reading

Forward Solutions Announces the Merger of George W. Mouk & Associates into Avision

HERSHEY, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) — Forward Solutions, a leading provider of outsources sales and marketing, is excited to announce the successful merger of George W. Mouk & Associates and Avision. This strategic collaboration marks a significant step towards enhancing service offerings and increasing market presence. George W. Mouk & Associates has been a leader in the foodservice and janitorial channel, serving customers in Louisiana, Mississippi, Arkansas, West Tennessee, Southern Alabama, and the Florida panhandle since 1970. Lee Mouk, President of George W. Mouk & Associates, shared his anticipation about this merger, stating, “I look forward to being part of a team of professional sales reps and the increased ability to serve our manufacturer and distributor partners.” This strategic...

Continue reading

Mullen Acquires Battery Pack Production Assets From Romeo Power

Assets purchased for approximately $3.5M includes equipment, inventory and IP for high volume EV battery pack production BREA, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces the purchase of battery pack production assets from Romeo Power for approximately $3.5 million. The deal includes equipment, inventory and intellectual property for high volume EV (electric vehicle) battery pack and module production. The Romeo Power assets include production lines for EV pack assembly and precision R&D module and pack development with associated inventory allowing for production of modules and vehicle battery packs. Additionally the purchased assets include battery testing and validation equipment,...

Continue reading

Global Lyme Disease Treatment Market Size to Reach USD 1,826.3 Million in 2032 | Emergen Research

Increase in the number of Lyme disease cases across the globe is a key factor driving market revenue growth Vancouver, Sept. 11, 2023 (GLOBE NEWSWIRE) — The global Lyme disease treatment market size was USD Million 850.0 in 2022 and is expected to register a revenue CAGR of 8.5% during the forecast period, according to latest analysis by Emergen Research. Increasing investment by major companies and rising development in healthcare facilities and diagnostic procedures across the globe are projected to support revenue growth of the Lyme disease treatment market during the forecast period. For both people and animals suspected of having been in touch with the disease, the greater accuracy of Spectroscopic testing may improve diagnosis procedures for Lyme disease. The new test could benefit mobile veterinary services for animals...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.